Clarus Ventures’s Astria Therapeutics ATXS Stock Holding History

Clarus Ventures’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$1.61M	Hold	33,470	–	–	0.38%	10
2018 Q2	$1.93M	Hold	33,470	–	–	0.68%	8
2018 Q1	$3.63M	Sell	33,470 -12,405	-27%	-$1.24M	3.72%	6
2017 Q4	$4.1M	Hold	45,875	–	–	4.08%	5
2017 Q3	$5.83M	Hold	45,875	–	–	4.75%	4
2017 Q2	$3.88M	Hold	45,875	–	–	3.57%	4
2017 Q1	$4.4M	Hold	45,875	–	–	3.28%	6
2016 Q4	$9.94M	Hold	45,875	–	–	6.55%	4
2016 Q3	$17M	Hold	45,875	–	–	10.42%	4
2016 Q2	$10.2M	Hold	45,875	–	–	8.91%	5
2016 Q1	$13.9M	Hold	45,875	–	–	10.42%	4
2015 Q4	$21.8M	Hold	45,875	–	–	15.3%	3
2015 Q3	$22.3M	Hold	45,875	–	–	12.81%	4
2015 Q2	$33.6M	Buy	+45,875	New	+$34.7M	14.78%	3

Other funds holding ATXS

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Clarus Ventures's ATXS Position: Q3 2018 in Review

Clarus Ventures held its Astria Therapeutics (ATXS) position steady in Q3 2018 at 33,470 shares worth $1.61M. The position accounts for 0.38% of the portfolio, ranked #10.

Clarus Ventures first reported a position in ATXS in Q2 2015 and has held it in 14 quarters since. The position peaked at $33.6M in Q2 2015. 28 funds tracked by Wall St. Rank hold ATXS as of Q3 2018.

Clarus Ventures held 33,470 shares of Astria Therapeutics worth $1.61M as of Q3 2018.
Clarus Ventures left its Astria Therapeutics share count unchanged in Q3 2018.
Astria Therapeutics made up 0.38% of Clarus Ventures's portfolio in Q3 2018, its #10 holding.
Clarus Ventures first reported a position in Astria Therapeutics in Q2 2015 and has held it in 14 quarters since.
Clarus Ventures's Astria Therapeutics position peaked at $33.6M in Q2 2015.
28 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2018.

Based on Clarus Ventures's 13F filing for Q3 2018, filed 14 Nov 2018.